When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOK - MyoKardia commences late-stage study of mavacamten in treatment-resistant heart disorder
MyoKardia Inc.
The first patient has been dosed in a Phase 3 clinical, VALOR-HCM, evaluating MyoKardia's (MYOK-0.5%) mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options, including those who have severe symptoms (NYHA Class IV).
More news on: MyoKardia, Inc., Healthcare stocks news,